Diagnosis and Management of Parathyroid Carcinoma.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
05 Sep 2024
05 Sep 2024
Historique:
received:
13
05
2024
accepted:
19
08
2024
medline:
5
9
2024
pubmed:
5
9
2024
entrez:
5
9
2024
Statut:
aheadofprint
Résumé
Parathyroid carcinoma (PC) is a rare malignancy, often characterized by the unregulated secretion of parathyroid hormone. The sequelae of severe hypercalcemia together with direct complications from tumor dissemination in patients with advanced disease are usually fatal. Due to its rarity, formal studies to guide the diagnosis and management of parathyroid carcinoma are lacking. However, recent data from case reports, case series, and registry studies suggest the emergence of new and effective treatment approaches for this understudied disease. We reviewed existing literature on the diagnosis and management of parathyroid carcinoma. Our findings suggest that traditional approaches such as surgical resection for both localized and metastatic diseases continue to play an important role in patient management. For patients with unresectable disease, newer systemic treatment approaches, including the use of temozolomide and tyrosine kinase inhibitors, may offer clinical benefit.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Clinical Pharmacology & Therapeutics © 2024 American Society for Clinical Pharmacology and Therapeutics.
Références
De Quervain, F. Parastruma maligna aberrata. Langenbecks Arch. Surg. 100, 334–353 (1909).
Lee, P.K., Jarosek, S.L., Virnig, B.A., Evasovich, M. & Tuttle, T.M. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 109, 1736–1741 (2007).
Roser, P. et al. Diagnosis and management of parathyroid carcinoma: a state‐of‐the‐art review. Endocr. Relat. Cancer 30, e220287 (2023).
Chen, Q. et al. Trial to predict malignancy of affected parathyroid glands in primary hyperparathyroidism. Endocr. J. 50, 527–534 (2003).
Rubin, M.R., Bilezikian, J.P., Birken, S. & Silverberg, S.J. Human chorionic gonadotropin measurements in parathyroid carcinoma. Eur. J. Endocrinol. 159, 469–474 (2008).
Shane, E. Clinical review 122: parathyroid carcinoma. J. Clin. Endocrinol. Metab. 86, 485–493 (2001).
Wilkins, B.J. & Lewis, J.S. Jr. Non‐functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head Neck Pathol. 3, 140–149 (2009).
Fingeret, A.L. Contemporary evaluation and management of parathyroid carcinoma. JCO Oncol. Pract. 17, 17–21 (2021).
Bae, J.H. et al. Preoperative predictive factors for parathyroid carcinoma in patients with primary hyperparathyroidism. J. Korean Med. Sci. 27, 890–895 (2012).
Sidhu, P.S., Talat, N., Patel, P., Mulholland, N.J. & Schulte, K.M. Ultrasound features of malignancy in the preoperative diagnosis of parathyroid cancer: a retrospective analysis of parathyroid tumours larger than 15 mm. Eur. Radiol. 21, 1865–1873 (2011).
Harari, A. et al. Parathyroid carcinoma: a 43‐year outcome and survival analysis. J. Clin. Endocrinol. Metab. 96, 3679–3686 (2011).
Christakis, I. et al. The diagnostic accuracy of neck ultrasound, 4D‐computed tomographyand sestamibi imaging in parathyroid carcinoma. Eur. J. Radiol. 95, 82–88 (2017).
Gardner, C. et al. Localization of metastatic parathyroid carcinoma by 18F FDG PET scanning. J. Clin. Endocrinol. Metabol. 95, 4844–4845 (2010).
Quinn, C.D., Chaudhary, F., Gould‐Simon, A., Chen, B., Bhandal, H.S. & Chaudhary, U. A case of a rare parathyroid hormone (PTH)‐producing neuroendocrine tumor. Am. J. Case Rep. 23, e935783 (2022).
Chen, Z., Fu, J., Shao, Q., Zhou, B. & Wang, F. 99mTc‐MIBI single photon emission computed tomography/computed tomography for the incidental detection of rare parathyroid carcinoma. Medicine 97, e12578 (2018).
Schantz, A. & Castleman, B. Parathyroid carcinoma. A study of 70 cases. Cancer 31, 600–605 (1973).
Sandelin, K., Tullgren, O. & Farnebo, L.O. Clinical course of metastatic parathyroid cancer. World J. Surg. 18, 594–598 (1994); discussion 599.
Karakas, E. et al. Development of a formula to predict parathyroid carcinoma in patients with primary hyperparathyroidism. World J. Surg. 36, 2605–2611 (2012).
Erickson, L.A. & Mete, O. Immunohistochemistry in diagnostic parathyroid pathology. Endocr. Pathol. 29, 113–129 (2018).
Wang, O. et al. Expression of Ki‐67, galectin‐3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors. Chin. Med. J. (Engl) 125, 2895–2901 (2012).
Bergero, N. et al. Galectin‐3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum. Pathol. 36, 908–914 (2005).
Fernandez‐Ranvier, G.G. et al. Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer 115, 334–344 (2009).
Silva‐Figueroa, A. et al. Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death‐ligand 1 expression and the presence of tumor‐infiltrating lymphocytes and macrophages. Surgery 164, 960–964 (2018).
Hundahl, S.A., Fleming, I.D., Fremgen, A.M. & Menck, H.R. Two hundred eighty‐six cases of parathyroid carcinoma treated in the U.S. between 1985‐1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 86, 538–544 (1999).
Brown, S. et al. Parathyroid carcinoma: increasing incidence and changing presentation. ANZ J. Surg. 81, 528–532 (2011).
Busaidy, N.L. et al. Parathyroid carcinoma: a 22‐year experience. Head Neck 26, 716–726 (2004).
Wang, P. et al. Clinical characteristics and treatment outcomes of parathyroid carcinoma: a retrospective review of 234 cases. Oncol. Lett. 14, 7276–7282 (2017).
Talat, N. & Schulte, K.M. Clinical presentation, staging and long‐term evolution of parathyroid cancer. Ann. Surg. Oncol. 17, 2156–2174 (2010).
Iihara, M. et al. Functional parathyroid carcinoma: long‐term treatment outcome and risk factor analysis. Surgery 142, 936–943 (2007).e1.
Simonds, W.F. Genetics of hyperparathyroidism, including parathyroid cancer. Endocrinol. Metab. Clin. North Am. 46, 405–418 (2017).
Torresan, F. & Iacobone, M. Clinical features, treatment, and surveillance of hyperparathyroidism‐jaw tumor syndrome: an up‐to‐date and review of the literature. Int. J. Endocrinol. 2019, 1761030 (2019).
Pacheco, M.C. Multiple endocrine neoplasia: a genetically diverse group of familial tumor syndromes. J. Pediatr. Genet. 5, 89–97 (2016).
Carpten, J.D. et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism‐jaw tumor syndrome. Nat. Genet. 32, 676–680 (2002).
Newey, P.J., Bowl, M.R. & Thakker, R.V. Parafibromin – functional insights. J. Intern. Med. 266, 84–98 (2009).
Hahn, M.A. et al. CDC73/HRPT2 CpG Island hypermethylation and mutation of 5′‐untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocr. Relat. Cancer 17, 273–282 (2010).
Corbetta, S. et al. Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr. Relat. Cancer 17, 135–146 (2010).
Chandrasekharappa, S.C. et al. Positional cloning of the gene for multiple endocrine neoplasia‐type 1. Science 276, 404–407 (1997).
Mathew, C.G. et al. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328, 527–528 (1987).
Shattuck, T.M. et al. Somatic and germ‐line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N. Engl. J. Med. 349, 1722–1729 (2003).
Haven, C.J. et al. Identification of MEN1 and HRPT2 somatic mutations in paraffin‐embedded (sporadic) parathyroid carcinomas. Clin. Endocrinol. (Oxf) 67, 370–376 (2007).
Krebs, L.J., Shattuck, T.M. & Arnold, A. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J. Clin. Endocrinol. Metab. 90, 5015–5017 (2005).
Marcocci, C., Cetani, F., Rubin, M.R., Silverberg, S.J., Pinchera, A. & Bilezikian, J.P. Parathyroid carcinoma. J. Bone Miner. Res. 23, 1869–1880 (2008).
Kang, H. et al. Genomic profiling of parathyroid carcinoma reveals genomic alterations suggesting benefit from therapy. Oncologist 24, 791–797 (2019).
Pandya, C. et al. Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight 2, e92061 (2017).
Shattuck, T.M. et al. Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin. Endocrinol. (Oxf) 59, 180–189 (2003).
Kowalski, G.J., Bednarczyk, A., Buła, G., Gawrychowska, A. & Gawrychowski, J. Parathyroid carcinoma – a study of 29 cases. Endokrynol. Pol. 73, 56–63 (2022).
Cetani, F., Pardi, E. & Marcocci, C. Parathyroid carcinoma. Front. Horm. Res. 51, 63–76 (2019).
Munson, N.D. et al. Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer 98, 2378–2384 (2003).
Asare, E.A. et al. Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the National Cancer Data Base (NCDB). Ann. Surg. Oncol. 22, 3990–3995 (2015).
Limberg, J. et al. The use and benefit of adjuvant radiotherapy in parathyroid carcinoma: a National Cancer Database Analysis. Ann. Surg. Oncol. 28, 502–511 (2021).
Perrier, N.D. et al. Hereditary endocrine tumours: current state‐of‐the‐art and research opportunities: new and future perspectives for parathyroid carcinoma. Endocr. Relat. Cancer 27, T53–T63 (2020).
Kebebew, E., Arici, C., Duh, Q. & Clark, O. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch. Surg. 136, 878–885 (2001).
Koyano, H. et al. Successful treatment by surgical removal of bone metastasis producing PTH: new approach to the management of metastatic parathyroid carcinoma. Intern. Med. 33, 697–702 (1994).
Yu, K.M. et al. Oligometastatic parathyroid carcinoma presenting as neck pain: a case report. Ear Nose Throat J. 102, 635–639 (2023).
Mirrakhimov, A.E. Hypercalcemia of malignancy: an update on pathogenesis and management. N. Am. J. Med. Sci. 7, 483–493 (2015).
Carroll, M.F. & Schade, D.S. A practical approach to hypercalcemia. Am. Fam. Physician 67, 1959–1966 (2003).
Ganesan, K., Goyal, A. & Roane, D. Bisphosphonate. In StatPearls (Treasure Island (FL), StatPearls Publishing LLC, 2024, StatPearls Publishing Copyright © 2024).
Hanley, D.A., Adachi, J.D., Bell, A. & Brown, V. Denosumab: mechanism of action and clinical outcomes. Int. J. Clin. Pract. 66, 1139–1146 (2012).
Ridefelt, P., Rydinge, J., Åkerström, G., Hellman, P. & Rastad, J. Somatostatin and octreotide interfere with calcium signalling in pancreatic β‐cells but not in normal and pathological parathyroid cells. Horm. Metab. Res. 28, 588–591 (1996).
Stueven, A.K. et al. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. Int. J. Mol. Sci. 20, 3049 (2019).
Camus, B. et al. Indications of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic and pulmonary neuroendocrine tumors: an updated review. J. Clin. Med. 10, 1267 (2021).
Strosberg, J. et al. Phase 3 trial of (177)Lu‐Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125–135 (2017).
Naik, C. & Basu, S. Peptide receptor radionuclide therapy with (177)Lu‐DOTATATE for metastatic neuroendocrine tumor occurring in association with multiple endocrine neoplasia type 1 and Cushing's syndrome. World J. Nucl. Med. 16, 126–132 (2017).
Wynne, A.G., van Heerden, J., Carney, J.A. & Fitzpatrick, L.A. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore) 71, 197–205 (1992).
Bukowski, R.M., Sheeler, L., Cunningham, J. & Esselstyn, C. Successful combination chemotherapy for metastatic parathyroid carcinoma. Arch. Intern. Med. 144, 399–400 (1984).
Calandra, D.B., Chejfec, G., Foy, B.K., Lawrence, A.M. & Paloyan, E. Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery 96, 1132–1137 (1984).
Chahinian, A.P., Holland, J.F., Nieburgs, H.E., Marinescu, A., Geller, S.A. & Kirschner, P. Metastatic nonfunctioning parathyroid carcinoma: ultrastructural evidence of secretory granules and response to chemotherapy. Am. J. Med. Sci. 282, 80–84 (1981).
Wesolowski, J.R., Rajdev, P. & Mukherji, S.K. Temozolomide (Temodar). AJNR Am. J. Neuroradiol. 31, 1383–1384 (2010).
Villano, J.L., Seery, T.E. & Bressler, L.R. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother. Pharmacol. 64, 647–655 (2009).
Hegi, M.E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005).
Kulke, M.H. et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol. 24, 401–406 (2006).
Kunz, P.L. et al. Randomized study of Temozolomide or Temozolomide and Capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG‐ACRIN E2211). J. Clin. Oncol. 41, 1359–1369 (2023).
Storvall, S. et al. MGMT promoter methylation and parathyroid carcinoma. J. Endocr. Soc. 3, 2114–2122 (2019).
Reddy, N., Dima, D., Kuri, D.M.V., McAneny, D., Kulke, M. & Lee, S.L. Use of temozolomide in parathyroid carcinoma with negative MGMT promoter methylation. J. Endocr. Soc. 5(Suppl 1), A1008 (2021).
Capdevila, J. et al. Lenvatinib in patients with advanced grade 1/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509). J. Clin. Oncol. 39, 2304–2312 (2021).
Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501–513 (2011).
Phan, A.T. et al. Pazopanib and depot octreotide in advanced, well‐differentiated neuroendocrine tumours: a multicentre, single‐group, phase 2 study. Lancet Oncol. 16, 695–703 (2015).
Hobday, T.J. et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J. Clin. Oncol. 25(18_suppl), 4504 (2007).
Castellano, D. et al. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). Eur. J. Cancer 49, 3780–3787 (2013).
Chan, J.A., Mayer, R.J., Jackson, N., Malinowski, P., Regan, E. & Kulke, M.H. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors. Cancer Chemother. Pharmacol. 71, 1241–1246 (2013).
Strosberg, J.R. et al. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr. Relat. Cancer 23, 411–418 (2016).
Chan, J. et al. LBA53 Alliance A021602: phase III, double‐blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET). Ann. Oncol. 34, S1292 (2023).
Grüllich, C. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Recent Results Cancer Res. 201, 207–214 (2014).
Choueiri, T.K. et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open‐label, phase 3 trial. Lancet Oncol. 17, 917–927 (2016).
Maroto, P. et al. Cabozantinib for the treatment of solid tumors: a systematic review. Ther. Adv. Med. Oncol. 14, 17588359221107112 (2022).
Chow, E., Tsang, R.W., Brierley, J.D. & Filice, S. Parathyroid carcinoma – the Princess Margaret hospital experience. Int. J. Radiat. Oncol. Biol. Phys. 41, 569–572 (1998).
Makino, H. et al. Successful control of hypercalcemia with sorafenib, evocalcet, and denosumab combination therapy for recurrent parathyroid carcinoma. Intern. Med. 61, 3383–3390 (2022).
Akirov, A. et al. The clinicopathological spectrum of parathyroid carcinoma. Front. Endocrinol. (Lausanne) 10, 731 (2019).
Kudo, M. et al. Lenvatinib versus sorafenib in first‐line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non‐inferiority trial. Lancet 391, 1163–1173 (2018).
Schlumberger, M., Tahara, M. & Wirth, L.J. Lenvatinib in radioiodine‐refractory thyroid cancer. N. Engl. J. Med. 372, 1868 (2015).
Teleanu, M.V. et al. Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling. Mol. Oncol. 17, 1343–1355 (2023).
Forbes, S.A. et al. COSMIC: somatic cancer genetics at high‐resolution. Nucleic Acids Res. 45(D1), D777–d783 (2017).
Bradwell, A.R. & Harvey, T.C. Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet 353, 370–373 (1999).
Betea, D. et al. Hormonal and biochemical normalization and tumor shrinkage induced by anti‐parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J. Clin. Endocrinol. Metab. 89, 3413–3420 (2004).
Sarquis, M. et al. Long‐term remission of disseminated parathyroid cancer following immunotherapy. Endocrine 67, 204–208 (2020).
Strosberg, J. et al. Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE‐158 study. Clin. Cancer Res. 26, 2124–2130 (2020).
Patel, S.P. et al. A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: high‐grade neuroendocrine neoplasm cohort. Cancer 127, 3194–3201 (2021).
Lenschow, C. et al. Case report: abdominal lymph node metastases of parathyroid carcinoma: diagnostic workup, molecular diagnosis, and clinical management. Front. Endocrinol. (Lausanne) 12, 643328 (2021).
Park, D., Airi, R. & Sherman, M. Microsatellite instability driven metastatic parathyroid carcinoma managed with the anti‐PD1 immunotherapy, pembrolizumab. BMJ Case Rep. 13, e235293 (2020).
Yang, R.K. et al. Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. Oncotarget 11, 600–618 (2020).